| Ytd | -20.10% | |
| 1y | -0.95% |
| Open | 3.04 | Prev Close | 3.05 | Low | 3.03 | High | 3.17 | Mkt Cap | 189.72M |
| Vol | 679.82K | Avg Vol | 618.45K | EPS | -1.97 | P/E | -1.59 | Forward P/E | -3.41 |
| Beta | 1.27 | Short Ratio | 4.44 | Inst. Own | 65.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 3.61 | 200-d Avg | 4.01 | 1yr Est | 17.10 |
VYGR News
- Data presented as Developing Topics poster at AAIC 2026 -LEXINGTON, Mass., July 13, 2026 (GLOBE NE
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE N
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer a
Jim Cramer recommended buying GE Vernova Inc. as Bernstein analyst initiated coverage with an Outper
LEXINGTON, Mass. , June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bi
Voyager Technologies Chairman and CEO Dylan Taylor joins ‘Mornings with Maria' to discuss SpaceX's r
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bio
- Dosing of adults with early Alzheimer's disease in clinical trial expected H2 2026 - - Comprehensi
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.47 per share versus the Zacks Conse
- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Mu
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, d
Longeveron (NASDAQ: LGVN - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report
Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with t
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.46 per share versus the Zacks Conse
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Confe
Voyager Therapeutics (NASDAQ: VYGR) outlined what CEO Al Sandrock described as three "pillars of val
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bio
Alvotech (NASDAQ: ALVO - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report)
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday